Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors.
Hiroshi MaedaKouichi MiuraNaoki MorimotoShunji WatanabeMamiko TsukuiYoshinari TakaokaHiroaki NomotoRie GokaNaoto SatoKazue MorishimaYasunaru SakumaNaohiro SataNoriyoshi FukushimaNorio IsodaHironori YamamotoPublished in: Cancers (2022)
TKI promoted a better OS in HCC patients with extrahepatic metastases compared to conventional therapies. However, TKI plus conventional therapies promoted no improvement in the prognosis of such patients.